Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study

BACKGROUND: Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. Ho...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Transl Med
Main Authors: Izumo, Takehiro, Tone, Mari, Kuse, Naoyuki, Awano, Nobuyasu, Tanaka, Atsuko, Jo, Tatsunori, Yoshimura, Hanako, Minami, Jonsu, Takada, Kohei, Inomata, Minoru
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7210162/
https://ncbi.nlm.nih.gov/pubmed/32395482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.04.01
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares